Cobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud Bosque
Desde la introducción de la vacuna contra la varicela a Colombia no se ha logrado una cobertura mayor al 90%. El objetivo de este trabajo es identificar las barreras de vacunación contra varicela en niños. Metodología. Estudio descriptivo realizado en la Fundación Salud Bosque; se estudiaron 27 paci...
- Autores:
-
Carvajal Barrios, Gustavo Adolfo
Ramos Rodríguez, Nicolás Ignacio
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2023
- Institución:
- Universidad Autónoma de Bucaramanga - UNAB
- Repositorio:
- Repositorio UNAB
- Idioma:
- spa
- OAI Identifier:
- oai:repository.unab.edu.co:20.500.12749/26187
- Palabra clave:
- Cobertura de Vacunación
Incidencia
Niño
Vacuna contra la Varicela
Varicela
Medical sciences
Life sciences
Vaccination Coverage
Incidence
Child
Chickenpox Vaccine
Chikenpox
Health sciences
Ciências médicas
Ciências da vida
Ciências da saúde
Cobertura Vacinal
Incidência
Criança
Vacina contra Varicela
Varicela
Ciencias médicas
Ciencias de la vida
Ciencias de la salud
- Rights
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
| id |
UNAB2_9d6187faaafbf55fd9d262d4209f205a |
|---|---|
| oai_identifier_str |
oai:repository.unab.edu.co:20.500.12749/26187 |
| network_acronym_str |
UNAB2 |
| network_name_str |
Repositorio UNAB |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Cobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud Bosque |
| dc.title.translated.eng.fl_str_mv |
Coverage of and Barriers to Varicella Vaccination in Children at Fundación Salud Bosque |
| dc.title.translated.por.fl_str_mv |
Cobertura e barreiras à vacinação contra varicela em crianças que consultaram a Fundação Salud Bosque |
| title |
Cobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud Bosque |
| spellingShingle |
Cobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud Bosque Cobertura de Vacunación Incidencia Niño Vacuna contra la Varicela Varicela Medical sciences Life sciences Vaccination Coverage Incidence Child Chickenpox Vaccine Chikenpox Health sciences Ciências médicas Ciências da vida Ciências da saúde Cobertura Vacinal Incidência Criança Vacina contra Varicela Varicela Ciencias médicas Ciencias de la vida Ciencias de la salud |
| title_short |
Cobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud Bosque |
| title_full |
Cobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud Bosque |
| title_fullStr |
Cobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud Bosque |
| title_full_unstemmed |
Cobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud Bosque |
| title_sort |
Cobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud Bosque |
| dc.creator.fl_str_mv |
Carvajal Barrios, Gustavo Adolfo Ramos Rodríguez, Nicolás Ignacio |
| dc.contributor.author.none.fl_str_mv |
Carvajal Barrios, Gustavo Adolfo Ramos Rodríguez, Nicolás Ignacio |
| dc.subject.spa.fl_str_mv |
Cobertura de Vacunación Incidencia Niño Vacuna contra la Varicela Varicela |
| topic |
Cobertura de Vacunación Incidencia Niño Vacuna contra la Varicela Varicela Medical sciences Life sciences Vaccination Coverage Incidence Child Chickenpox Vaccine Chikenpox Health sciences Ciências médicas Ciências da vida Ciências da saúde Cobertura Vacinal Incidência Criança Vacina contra Varicela Varicela Ciencias médicas Ciencias de la vida Ciencias de la salud |
| dc.subject.keywords.eng.fl_str_mv |
Medical sciences Life sciences Vaccination Coverage Incidence Child Chickenpox Vaccine Chikenpox Health sciences |
| dc.subject.keywords.por.fl_str_mv |
Ciências médicas Ciências da vida Ciências da saúde Cobertura Vacinal Incidência Criança Vacina contra Varicela Varicela |
| dc.subject.lemb.eng.fl_str_mv |
Ciencias médicas Ciencias de la vida Ciencias de la salud |
| description |
Desde la introducción de la vacuna contra la varicela a Colombia no se ha logrado una cobertura mayor al 90%. El objetivo de este trabajo es identificar las barreras de vacunación contra varicela en niños. Metodología. Estudio descriptivo realizado en la Fundación Salud Bosque; se estudiaron 27 pacientes, 18 hombres (67%) y 9 mujeres (33%), incluyendo menores de 18 años con varicela, y excluyendo pacientes con enfermedades ampollosas distintas a varicela y quemaduras. Se hizo una caracterización demográfica. Para las variables cuantitativas se emplearon promedios y desviación estándar, y para las cualitativas la razón de proporción con Stata V12®. Resultados. La incidencia de varicela fue del 0.2%, solo 9 pacientes (33%) habían recibido la primera dosis de la vacuna, ninguno la segunda dosis. El 92.5% requirió incapacidad; el 89% analgésicos; el 63% antihistamínicos y el 26% antibióticos. Discusión. El estudio realizado demuestra una incidencia significativamente menor en contraste con otras cohortes internacionales. En Colombia no se ha alcanzado la cobertura de la vacunación contra la varicela lograda en Uruguay, Costa Rica, Estados Unidos, Australia, Europa y Taiwán, dadas las mismas barreras en su aplicación, mientras que en África no se ha introducido la vacuna contra la varicela porque existen otras prioridades como la desnutrición, la malaria y la infección por Virus de la Inmunodeficiencia Humana. Conclusiones. La cobertura de la vacunación no se ha logrado por barreras modificables que incrementan la incidencia y carga de la enfermedad por costos debido a incapacidad, manejo farmacológico y ausentismo escolar. |
| publishDate |
2023 |
| dc.date.issued.none.fl_str_mv |
2023-04-11 |
| dc.date.accessioned.none.fl_str_mv |
2024-08-23T20:30:55Z |
| dc.date.available.none.fl_str_mv |
2024-08-23T20:30:55Z |
| dc.type.eng.fl_str_mv |
Article |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.driver.none.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.local.spa.fl_str_mv |
Artículo |
| dc.type.coar.none.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.redcol.none.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.identifier.issn.spa.fl_str_mv |
i-ISSN 0123-7047 e-ISSN 2382-4603 |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12749/26187 |
| dc.identifier.instname.spa.fl_str_mv |
instname:Universidad Autónoma de Bucaramanga UNAB |
| dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional UNAB |
| dc.identifier.repourl.spa.fl_str_mv |
repourl:https://repository.unab.edu.co |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.29375/01237047.4165 |
| identifier_str_mv |
i-ISSN 0123-7047 e-ISSN 2382-4603 instname:Universidad Autónoma de Bucaramanga UNAB reponame:Repositorio Institucional UNAB repourl:https://repository.unab.edu.co |
| url |
http://hdl.handle.net/20.500.12749/26187 https://doi.org/10.29375/01237047.4165 |
| dc.language.iso.spa.fl_str_mv |
spa |
| language |
spa |
| dc.relation.spa.fl_str_mv |
https://revistas.unab.edu.co/index.php/medunab/article/view/4165/3800 |
| dc.relation.uri.spa.fl_str_mv |
https://revistas.unab.edu.co/index.php/medunab/issue/view/289 |
| dc.relation.references.none.fl_str_mv |
Lerman SJ. Why is Chickenpox Called Chickenpox? Clin Pediatr [Internet]. 1981;20(2): 111-112. doi: https:// doi.org/10.1177/000992288102000205 Heininger U, Seward JF. Varicella. Lancet [Internet]. 2006;368(9544):1365–1376. doi: https://doi.org/10.1016/ S0140-6736(06)69561-5 Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet [Internet]. 1974;304(7892):1288-1290. doi: https://doi.org/10.1016/ s0140-6736(74)90144-5 Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep [Internet]. 1996;45(RR-11):1- 36. Recuperado a partir de: https://www.cdc.gov/mmwr/ preview/mmwrhtml/00042990.html López AS, Guris D, Zimmerman L, Gladden L, Moore T, Haselow DT, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?. Pediatrics [Internet]. 2006;117(6):e1070-e1077. doi: https://doi.org/10.1542/peds.2005-2085 MINSALUD. Introducción de la vacuna contra la varicela y modificación en el esquema nacional de vacunación de Colombia. Circular Externa No. 027 de 2015. [Internet]. Recuperado a partir de: https://www.minsalud.gov.co/ Normatividad_Nuevo/Circular%200027%20de%20 2015.pdf Espinal CA, Upegui G, Cristancho LM. Indicadores epidemiológicos de varicela en Colombia. Infectio [Internet]. 1998;2(2):77-85. Recuperado a partir de: https://www.revistainfectio.org/index.php/infectio/ article/view/429 Bardach A, Cafferata ML, Klein K, Cormick G, Gibbons L, Ruvinsky S. Incidence and Use of Resources for Chickenpox and Herpes Zoster in Latin America and the Caribbean—A Systematic Review and Meta-analysis. Pediatr Infect Dis J [Internet]. 2012;31(12):1263–1268. doi: https://doi.org/10.1097/INF.0b013e31826ff3a5 MINSALUD. Se refuerza la lucha contra la varicela: Niños de 5 años a ponerse la segunda dosis. [Internet]. Recuperado a partir de: https://www.minsalud.gov.co/ Paginas/Se-refuerza-lucha-contra-la-varicela-Niños-de- 5-años-a-ponerse-la-segunda-dosis-.aspx Instituto Nacional de Salud – INS. Boletín Epidemiológico Semanal. Semana epidemiológica 07, del 9 al 15 de febrero de 2020 [Internet]. Recuperado a partir de: https://www.ins.gov.co/buscadoreventos/ BoletinEpidemiologico/2020_Boletin_ epidemiologico_semana_7.pdf Varela FH, Araújo-Pinto L, Scotta MC. Global impact of varicella vaccination programs. Hum Vaccin Immunother [Internet]. 2019;15(3):645-657. doi: https://doi.org/10.1080/21645515.2018.1546525 Instituto Nacional de Salud – INS. Protocolo de vigilancia de varicela, versión 03 diciembre 29 de 2020. [Internet]. Recuperado a partir de: https://www.ins.gov. co/buscador-eventos/Lineamientos/Pro_Varicela.pdf López AS, Zhang J, Marin M. Epidemiology of Varicella During the 2-Dose Varicella Vaccination Program - United States, 2005-2014. MMWR Morb Mortal Wkly Rep [Internet]. 2016;2;65(34):902-905. doi: https://doi. org/10.15585/mmwr.mm6534a4 Streng A, Grote V, Rack-Hoch A, Liese JG. Decline of Neurologic Varicella Complications in Children During the First Seven Years After Introduction of Universal Varicella Vaccination in Germany, 2005–2011. Pediatr Infect Dis J [Internet]. 2017;36(1):79–86. doi: https:// doi.org/10.1097/INF.0000000000001356 Helmuth IG, Poulsen A, Suppli CH, Mølbak K. Varicella in Europe - A review of the epidemiology and experience with vaccination. Vaccine [Internet]. 2015;33(21):2406-2413. doi: https://doi.org/10.1016/j. vaccine.2015.03.055 Falleiros-Arlant LH, Pirez-Garcia MC, Avila-Aguero ML, Cashat M, Parellada CI, Wolfson LJ. Burden of varicella in Latin America and the Caribbean: findings from a systematic literature review. BMC Public Health [Internet]. 2019;8:19(2):175-183. doi: https://doi. org/10.1186/s12889-019-6795-0 Hussey H, Abdullahi L, Collins J, Muloiwa R, Hussey G, Kagina B. Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review. BMC Infect Dis. [Internet]. 2017;17(1):1-11. doi: https://doi. org/10.1186/s12879-017-2815-9 Nanishi E, Hoshina T, Takada H, Ishimura M, Nishio H, Uehara T, et al. A nationwide survey of common viral infections in childhood among patients with primary immunodeficiency diseases. J Infect [Internet]. 2016;73(4):358-368. doi: https://doi.org/10.1016/j. jinf.2016.07.018 Helmuth IG, Poulsen A, Mølbak K. A national registerbased study of paediatric varicella hospitalizations in Denmark 2010–2016. Epidemiol Infect [Internet]. 2017;145(13):2683-2693. doi: https://doi.org/10.1017/ S0950268817001777 Mirinaviciute G, Kristensen E, Nakstad B, Flem E. Varicella-Related Primary Health-care Visits, Hospitalizations and Mortality in Norway, 2008-2014. Pediatr Infect Dis J [Internet]. 2017;36(11):1032-1038. doi: https://doi.org/10.1097/inf.0000000000001656 Purssell E, While AE. Does the Use of Antipyretics in Children Who Have Acute Infections Prolong Febrile Illness? A Systematic Review and Meta-Analysis. J Pediatr [Internet]. 2013;163(3):822-827.e1-2. doi: https:// doi.org/10.1016/j.jpeds.2013.03.069 Chiappini E, Venturini E, Remaschi G, Principi N, Longhi R, Tovo PA, et al. 2016 Update of the Italian Pediatric Society Guidelines for Management of Fever in Children. J Pediatr [Internet]. 2017;180:1-7.e1. doi: https://doi.org/10.1016/j.jpeds.2016.09.043 Peetoom KK, Smits JJ, Ploum LJ, Verbakel JY, Dinant,1 Jochen GJ, et al. Does well-child care education improve consultations and medication management for childhood fever and common infections? A systematic review. Arch Dis Child [Internet]. 2017;102(3):261-267. doi: https:// doi.org/10.1136/archdischild-2016-311042 Tebruegge M, Kuruvilla M, Margarson I. Does the use of calamine or antihistamine provide symptomatic relief from pruritus in children with varicella zoster infection? Arch Dis Child. [Internet]. 2006;91(12):1035-1036. doi: https://doi.org/10.1136/adc.2006.105114 Manistarski M, Levin D, Dvir R, Berger-Achituv S, Rosenfeld-Keidar H, Grisaru-Soen G et al. Lessons from an Outbreak of Varicella Infection in Pediatric Hemato- Oncology Patients. Pediatr Infect Dis J [Internet]. 2018;37(7):649-653. doi: https://doi.org/10.1097/ inf.0000000000001920 Brotons M, Campins M, Méndez L, Juste C, Rodrigo JA, Martínez X, et al. Effectiveness of Varicella Vaccines as Postexposure Prophylaxis. Pediatr Infect Dis J [Internet]. 2010;29(1):10–13. doi: https://doi.org/10.1097/ inf.0b013e3181b36022 Bapat P, Koren G. The role of VariZIG in pregnancy. Expert Rev. Vaccines [Internet]. 2013;12(11):1243–1248. doi: https://doi.org/10.1586/14760584.2013.844651 Mandelbrot L. Fetal varicella – diagnosis, management, and outcome. Prenat Diagn [Internet]. 2012;32(6):511– 518. doi: https://doi.org/10.1002/pd.3843 Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review. BMC Public Health [Internet]. 2016;16:1-17. doi: https://doi.org/10.1186/ s12889-016-2845-z Vezzosi L, Santagati G, Angelillo IF. Knowledge, attitudes, and behaviors of parents towards varicella and its vaccination. BMC Infect Dis. [Internet]. 2017;17(1):1- 8. doi: https://doi.org/10.1186/s12879-017-2247-6 van Lier A, Tostmann A, Harmsen IA, de Melker HE, Hautvast JA, Ruijs WL. Negative attitude and low intention to vaccinate universally against varicela among public health professionals and parents in the Netherlands: two internet surveys. BMC Infect Dis [Internet]. 2016;16:1-12. doi: https://doi.org/10.1186/ s12879-016-1442-1 Larson HJ, Jarrett C, Eckersberger E, Smith D, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012. Vaccine [Internet]. 2014;32(19):2150–2159. doi: https://doi. org/10.1016/j.vaccine.2014.01.081 Instituto Nacional de Salud – INS. Boletín Epidemiológico Semanal. Semana epidemiológica 02, del 9 al 15 de enero de 2022. [Internet]. Recuperado a partir de: https://www.ins.gov.co/buscadoreventos/ BoletinEpidemiologico/2022_Boletin_ epidemiologico_semana_2.pdf Lee YH, Choe YJ, Cho SI, Kang CR, Bang JH, Oh MD, et al. Effectiveness of Varicella Vaccination Program in Preventing Laboratory-Confirmed Cases in Children in Seoul, Korea. J Korean Med Sci [Internet]. 2016;31(12):1897-1901. doi: https://doi.org/10.3346/ jkms.2016.31.12.1897 Siedler A, Rieck T, Tolksdorf K. Strong Additional Effect of a Second Varicella Vaccine Dose in Children in Germany, 2009-2014. J Pediatr [Internet]. 2016;173:202-206.e2. doi: https://doi.org/10.1016/j. jpeds.2016.02.040 Leung J, Harpaz R. Impact of the Maturing Varicella Vaccination Program on Varicella and Related Outcomes in the United States: 1994–2012. J Pediat Infect Dis Soc [Internet]. 2016;5(4):395-402. doi: https://doi. org/10.1093/jpids/piv044 Hobbelen PHF, Stowe J, Amirthalingam G, Miller L, van Hoek AJ, The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. J Infect [Internet]. 2016;73(3):241-253. doi: https://doi. org/10.1016/j.jinf.2016.05.008 Wormsbecker AE, Wang J, Rosella LC, Kwong JC, Seo CY, Crowcroft NS, et al. Twenty Years of Medically- Attended Pediatric Varicella and Herpes Zoster in Ontario, Canada: A Population-Based Study. PLoS ONE [Internet]. 2015;10(7):1-13. doi: https://doi. org/10.1371/journal.pone.0129483 Xu Y, Liu Y, Zhang X, Zhang X, Du J, Cai Y, et al. Epidemiology of varicella and effectiveness of varicella vaccine in Hangzhou, China, 2019. Hum Vaccin Immunother [Internet]. 2021;17(1):211-216. doi: https://doi.org/10.1080/21645515.2020.1769395 Abdullat M, Hayajneh W, Banni-Issa A, Alshurman A, Marar B, Al-Hajajrah A, et al. Use of health care resources for varicella in the paediatric population, Jordan. East Mediterr Health J [Internet]. 2021;27(2):159-166. doi: https://doi.org/10.26719/2021.27.2.159 Chacon-Cruz E, Meroc E, Costa-Clemens SA, Clemens R, Verstraeten T. Economic Evaluation of Universal Varicella Vaccination in Mexico. Pediatr Infect Dis J [Internet]. 2022;41(5):439-444. doi: https://doi. org/10.1097/inf.0000000000003448 Akpo EIH, Cristeau O, Hunjan M, Casabona G. Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom. Clin Infect Dis [Internet]. 2021;73(11):e3617-e3626. doi: https://doi.org/10.1093/cid/ciaa1708 Marijam A, Safonova E, Scherbakov M, Shpeer E, Van Oorschot D, Rudakova A, et al. Cost effectiveness and budget impact of universal varicella vaccination in Russia. Hum Vaccin Immunother [Internet]. 2022;18(5):2045152. doi: https://doi.org/10.1080/21645 515.2022.2045152 Heininger U, Pillsbury M, Samant S, Lienert F, Guggisberg P, Gani R, et al. Health Impact and Costeffectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland. Pediatr Infect Dis J [Internet]. 2021;40(6):e217-e221. doi: https:// doi.org/10.1097/inf.0000000000003136 Ávila-Agüero ML, Beltrán S, Brea-del Castillo J, Castillo-Díaz ME, Chaparro LE, Deseda C, et al. Varicella epidemiology in Latin America and the Caribbean. Expert Rev Vaccines [Internet]. 2018;17(2):175-183. doi: https://doi.org/10.1080/14760584.2018.1418327 Alvis-Guzmán N, Paternina-Caicedo A, Alvis-Estrada L, De la Hoz-Restrepo F. Costos directos de varicela complicada en una población pediátrica de Colombia. Rev Salud Pública [Internet]. 2011;13(6):921-929. doi: https://doi.org/10.1590/s0124-00642011000600005 Torres JP, Maza V, Izquierdo G, Contardo V, Conca N, Ducasse K, et al. Caracterización clínica y de costos de la hospitalización asociada a varicela en niños de la Región Metropolitana y de Valparaíso, Chile. Rev Chilena Infectol [Internet]. 2021;38(5):647-654. doi: https://doi. org/10.4067/s0716-10182021000500647 Maglione MA, Das L, Raaen L, Smith A, Chari R, Newberry S, et al. Safety of Vaccines Used for Routine Immunization of U.S. Children: A Systematic Review. Pediatrics [Internet]. 2014;134(2):325–337. doi: https:// doi.org/10.1542/peds.2014-1079 Meyer C, Reiter S. Impfgegner und Impfskeptiker Geschichte, Hintergründe, Thesen, Umgang. Bundesgesundheitsbl-Gesundheitsforsch- Gesundheitsschutz [Internet]. 2004;47(12):1182–1188. doi: https://doi.org/10.1007/s00103-004-0953-x |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
| dc.rights.local.spa.fl_str_mv |
Abierto (Texto Completo) |
| dc.rights.creativecommons.*.fl_str_mv |
Atribución-NoComercial-SinDerivadas 2.5 Colombia |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ Abierto (Texto Completo) Atribución-NoComercial-SinDerivadas 2.5 Colombia http://purl.org/coar/access_right/c_abf2 |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.grantor.spa.fl_str_mv |
Universidad Autónoma de Bucaramanga UNAB |
| dc.publisher.faculty.spa.fl_str_mv |
Facultad Ciencias de la Salud |
| dc.source.spa.fl_str_mv |
Vol. 26 Núm. 1 (2023): abril - julio 2023: Niño, Adolescente, Varicela; 12-20 |
| institution |
Universidad Autónoma de Bucaramanga - UNAB |
| bitstream.url.fl_str_mv |
https://repository.unab.edu.co/bitstream/20.500.12749/26187/1/Art%c3%adculo.pdf https://repository.unab.edu.co/bitstream/20.500.12749/26187/2/license.txt https://repository.unab.edu.co/bitstream/20.500.12749/26187/3/Art%c3%adculo.pdf.jpg |
| bitstream.checksum.fl_str_mv |
15483658392edbcc1efe68f6fd024617 737346e09d47a3db691f1370de49426a 8f6fb43ff5841648fc6f3d88bc2d2cf9 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional | Universidad Autónoma de Bucaramanga - UNAB |
| repository.mail.fl_str_mv |
repositorio@unab.edu.co |
| _version_ |
1814278471847772160 |
| spelling |
Carvajal Barrios, Gustavo Adolfobc48cd94-f132-4220-a2ac-bbb9def9c1e6Ramos Rodríguez, Nicolás Ignaciof28b3e31-3910-4447-86a2-d8bd1cdc21192024-08-23T20:30:55Z2024-08-23T20:30:55Z2023-04-11i-ISSN 0123-7047e-ISSN 2382-4603http://hdl.handle.net/20.500.12749/26187instname:Universidad Autónoma de Bucaramanga UNABreponame:Repositorio Institucional UNABrepourl:https://repository.unab.edu.cohttps://doi.org/10.29375/01237047.4165Desde la introducción de la vacuna contra la varicela a Colombia no se ha logrado una cobertura mayor al 90%. El objetivo de este trabajo es identificar las barreras de vacunación contra varicela en niños. Metodología. Estudio descriptivo realizado en la Fundación Salud Bosque; se estudiaron 27 pacientes, 18 hombres (67%) y 9 mujeres (33%), incluyendo menores de 18 años con varicela, y excluyendo pacientes con enfermedades ampollosas distintas a varicela y quemaduras. Se hizo una caracterización demográfica. Para las variables cuantitativas se emplearon promedios y desviación estándar, y para las cualitativas la razón de proporción con Stata V12®. Resultados. La incidencia de varicela fue del 0.2%, solo 9 pacientes (33%) habían recibido la primera dosis de la vacuna, ninguno la segunda dosis. El 92.5% requirió incapacidad; el 89% analgésicos; el 63% antihistamínicos y el 26% antibióticos. Discusión. El estudio realizado demuestra una incidencia significativamente menor en contraste con otras cohortes internacionales. En Colombia no se ha alcanzado la cobertura de la vacunación contra la varicela lograda en Uruguay, Costa Rica, Estados Unidos, Australia, Europa y Taiwán, dadas las mismas barreras en su aplicación, mientras que en África no se ha introducido la vacuna contra la varicela porque existen otras prioridades como la desnutrición, la malaria y la infección por Virus de la Inmunodeficiencia Humana. Conclusiones. La cobertura de la vacunación no se ha logrado por barreras modificables que incrementan la incidencia y carga de la enfermedad por costos debido a incapacidad, manejo farmacológico y ausentismo escolar.Ever since the introduction of the varicella vaccine in Colombia, coverage has not surpassed 90%. The objective of this work is to identify the barriers to varicella vaccination in children. Methodology. A descriptive study conducted at Fundación Salud Bosque. 27 patients were studied - 18 males (67%) and 9 females (33%) - including children under 18 years of age with varicella, and excluding patients with blistering diseases other than varicella and burns. A demographic characterization was conducted. Averages and standard deviations were used for quantitative variables, and the proportion ratio was used for qualitative variables with Stata V12®. Results. The incidence of varicella was 0.2%. Only 9 patients (33%) had received the first dose of the vaccine, and none had received the second dose. 92.5% required sick leave, 89% required painkillers, 63% required antihistamines, and 26% required antibiotics. Discussion. The conducted study shows a significantly lower incidence compared to other international cohorts. Colombia has not achieved the varicella vaccination coverage of Uruguay, Costa Rica, the United States, Australia, Europe and Taiwan due to the barriers to applying it. Meanwhile, the varicella vaccine has not been introduced in Africa because there are other priorities, such as malnutrition, malaria and the Human Immunodeficiency Virus infection. Conclusions. Vaccination coverage has not been achieved because of modifiable barriers that increase the incidence and burden of the disease due to costs of sick leave, pharmacological treatment and school absenteeism.Desde a introdução da vacina contra varicela na Colômbia, não foi alcançada uma cobertura superior a 90%. O objetivo deste trabalho é identificar as barreiras à vacinação contra varicela em crianças. Metodologia. Estudo descritivo realizado na Fundação Salud Bosque. Foram estudados 27 pacientes, 18 homens (67%) e 9 mulheres (33%), incluindo crianças menores de 18 anos com varicela e excluindo pacientes com outras doenças bolhosas que não varicela e queimaduras. Foi feita uma caracterização demográfica. Média e desvio padrão foram utilizados para as variáveis quantitativas e, para variáveis qualitativas, a razão de proporção com Stata V12®. Resultados. A incidência de varicela foi de 0.2%, apenas 9 pacientes (33%) receberam a primeira dose da vacina, nenhum a segunda dose. 92,5% requeriam atestado; 89% analgésicos; 63% anti-histamínicos e 26% antibióticos. Discussão. O estudo realizado mostra uma incidência significativamente menor em comparação com outras coortes internacionais. A Colômbia não tem atingido a cobertura vacinal contra a varicela alcançada no Uruguai, Costa Rica, Estados Unidos, Austrália, Europa e Taiwan, dadas as mesmas barreiras em sua aplicação, enquanto na África a vacina contra a varicela não foi introduzida. porque existem outras prioridades como a desnutrição, a malária e a infecção pelo Vírus da Imunodeficiência Humana. Conclusões. A cobertura vacinal não foi alcançada dadas as barreiras modificáveis que aumentam a incidência e carga da doença devido aos custos por atestados, manejo farmacológico e absenteísmo escolar.application/pdfspahttps://revistas.unab.edu.co/index.php/medunab/article/view/4165/3800https://revistas.unab.edu.co/index.php/medunab/issue/view/289Lerman SJ. Why is Chickenpox Called Chickenpox? Clin Pediatr [Internet]. 1981;20(2): 111-112. doi: https:// doi.org/10.1177/000992288102000205Heininger U, Seward JF. Varicella. Lancet [Internet]. 2006;368(9544):1365–1376. doi: https://doi.org/10.1016/ S0140-6736(06)69561-5Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet [Internet]. 1974;304(7892):1288-1290. doi: https://doi.org/10.1016/ s0140-6736(74)90144-5Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep [Internet]. 1996;45(RR-11):1- 36. Recuperado a partir de: https://www.cdc.gov/mmwr/ preview/mmwrhtml/00042990.htmlLópez AS, Guris D, Zimmerman L, Gladden L, Moore T, Haselow DT, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?. Pediatrics [Internet]. 2006;117(6):e1070-e1077. doi: https://doi.org/10.1542/peds.2005-2085MINSALUD. Introducción de la vacuna contra la varicela y modificación en el esquema nacional de vacunación de Colombia. Circular Externa No. 027 de 2015. [Internet]. Recuperado a partir de: https://www.minsalud.gov.co/ Normatividad_Nuevo/Circular%200027%20de%20 2015.pdfEspinal CA, Upegui G, Cristancho LM. Indicadores epidemiológicos de varicela en Colombia. Infectio [Internet]. 1998;2(2):77-85. Recuperado a partir de: https://www.revistainfectio.org/index.php/infectio/ article/view/429Bardach A, Cafferata ML, Klein K, Cormick G, Gibbons L, Ruvinsky S. Incidence and Use of Resources for Chickenpox and Herpes Zoster in Latin America and the Caribbean—A Systematic Review and Meta-analysis. Pediatr Infect Dis J [Internet]. 2012;31(12):1263–1268. doi: https://doi.org/10.1097/INF.0b013e31826ff3a5MINSALUD. Se refuerza la lucha contra la varicela: Niños de 5 años a ponerse la segunda dosis. [Internet]. Recuperado a partir de: https://www.minsalud.gov.co/ Paginas/Se-refuerza-lucha-contra-la-varicela-Niños-de- 5-años-a-ponerse-la-segunda-dosis-.aspxInstituto Nacional de Salud – INS. Boletín Epidemiológico Semanal. Semana epidemiológica 07, del 9 al 15 de febrero de 2020 [Internet]. Recuperado a partir de: https://www.ins.gov.co/buscadoreventos/ BoletinEpidemiologico/2020_Boletin_ epidemiologico_semana_7.pdfVarela FH, Araújo-Pinto L, Scotta MC. Global impact of varicella vaccination programs. Hum Vaccin Immunother [Internet]. 2019;15(3):645-657. doi: https://doi.org/10.1080/21645515.2018.1546525Instituto Nacional de Salud – INS. Protocolo de vigilancia de varicela, versión 03 diciembre 29 de 2020. [Internet]. Recuperado a partir de: https://www.ins.gov. co/buscador-eventos/Lineamientos/Pro_Varicela.pdfLópez AS, Zhang J, Marin M. Epidemiology of Varicella During the 2-Dose Varicella Vaccination Program - United States, 2005-2014. MMWR Morb Mortal Wkly Rep [Internet]. 2016;2;65(34):902-905. doi: https://doi. org/10.15585/mmwr.mm6534a4Streng A, Grote V, Rack-Hoch A, Liese JG. Decline of Neurologic Varicella Complications in Children During the First Seven Years After Introduction of Universal Varicella Vaccination in Germany, 2005–2011. Pediatr Infect Dis J [Internet]. 2017;36(1):79–86. doi: https:// doi.org/10.1097/INF.0000000000001356Helmuth IG, Poulsen A, Suppli CH, Mølbak K. Varicella in Europe - A review of the epidemiology and experience with vaccination. Vaccine [Internet]. 2015;33(21):2406-2413. doi: https://doi.org/10.1016/j. vaccine.2015.03.055Falleiros-Arlant LH, Pirez-Garcia MC, Avila-Aguero ML, Cashat M, Parellada CI, Wolfson LJ. Burden of varicella in Latin America and the Caribbean: findings from a systematic literature review. BMC Public Health [Internet]. 2019;8:19(2):175-183. doi: https://doi. org/10.1186/s12889-019-6795-0Hussey H, Abdullahi L, Collins J, Muloiwa R, Hussey G, Kagina B. Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review. BMC Infect Dis. [Internet]. 2017;17(1):1-11. doi: https://doi. org/10.1186/s12879-017-2815-9Nanishi E, Hoshina T, Takada H, Ishimura M, Nishio H, Uehara T, et al. A nationwide survey of common viral infections in childhood among patients with primary immunodeficiency diseases. J Infect [Internet]. 2016;73(4):358-368. doi: https://doi.org/10.1016/j. jinf.2016.07.018Helmuth IG, Poulsen A, Mølbak K. A national registerbased study of paediatric varicella hospitalizations in Denmark 2010–2016. Epidemiol Infect [Internet]. 2017;145(13):2683-2693. doi: https://doi.org/10.1017/ S0950268817001777Mirinaviciute G, Kristensen E, Nakstad B, Flem E. Varicella-Related Primary Health-care Visits, Hospitalizations and Mortality in Norway, 2008-2014. Pediatr Infect Dis J [Internet]. 2017;36(11):1032-1038. doi: https://doi.org/10.1097/inf.0000000000001656Purssell E, While AE. Does the Use of Antipyretics in Children Who Have Acute Infections Prolong Febrile Illness? A Systematic Review and Meta-Analysis. J Pediatr [Internet]. 2013;163(3):822-827.e1-2. doi: https:// doi.org/10.1016/j.jpeds.2013.03.069Chiappini E, Venturini E, Remaschi G, Principi N, Longhi R, Tovo PA, et al. 2016 Update of the Italian Pediatric Society Guidelines for Management of Fever in Children. J Pediatr [Internet]. 2017;180:1-7.e1. doi: https://doi.org/10.1016/j.jpeds.2016.09.043Peetoom KK, Smits JJ, Ploum LJ, Verbakel JY, Dinant,1 Jochen GJ, et al. Does well-child care education improve consultations and medication management for childhood fever and common infections? A systematic review. Arch Dis Child [Internet]. 2017;102(3):261-267. doi: https:// doi.org/10.1136/archdischild-2016-311042Tebruegge M, Kuruvilla M, Margarson I. Does the use of calamine or antihistamine provide symptomatic relief from pruritus in children with varicella zoster infection? Arch Dis Child. [Internet]. 2006;91(12):1035-1036. doi: https://doi.org/10.1136/adc.2006.105114Manistarski M, Levin D, Dvir R, Berger-Achituv S, Rosenfeld-Keidar H, Grisaru-Soen G et al. Lessons from an Outbreak of Varicella Infection in Pediatric Hemato- Oncology Patients. Pediatr Infect Dis J [Internet]. 2018;37(7):649-653. doi: https://doi.org/10.1097/ inf.0000000000001920Brotons M, Campins M, Méndez L, Juste C, Rodrigo JA, Martínez X, et al. Effectiveness of Varicella Vaccines as Postexposure Prophylaxis. Pediatr Infect Dis J [Internet]. 2010;29(1):10–13. doi: https://doi.org/10.1097/ inf.0b013e3181b36022Bapat P, Koren G. The role of VariZIG in pregnancy. Expert Rev. Vaccines [Internet]. 2013;12(11):1243–1248. doi: https://doi.org/10.1586/14760584.2013.844651Mandelbrot L. Fetal varicella – diagnosis, management, and outcome. Prenat Diagn [Internet]. 2012;32(6):511– 518. doi: https://doi.org/10.1002/pd.3843Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review. BMC Public Health [Internet]. 2016;16:1-17. doi: https://doi.org/10.1186/ s12889-016-2845-zVezzosi L, Santagati G, Angelillo IF. Knowledge, attitudes, and behaviors of parents towards varicella and its vaccination. BMC Infect Dis. [Internet]. 2017;17(1):1- 8. doi: https://doi.org/10.1186/s12879-017-2247-6van Lier A, Tostmann A, Harmsen IA, de Melker HE, Hautvast JA, Ruijs WL. Negative attitude and low intention to vaccinate universally against varicela among public health professionals and parents in the Netherlands: two internet surveys. BMC Infect Dis [Internet]. 2016;16:1-12. doi: https://doi.org/10.1186/ s12879-016-1442-1Larson HJ, Jarrett C, Eckersberger E, Smith D, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012. Vaccine [Internet]. 2014;32(19):2150–2159. doi: https://doi. org/10.1016/j.vaccine.2014.01.081Instituto Nacional de Salud – INS. Boletín Epidemiológico Semanal. Semana epidemiológica 02, del 9 al 15 de enero de 2022. [Internet]. Recuperado a partir de: https://www.ins.gov.co/buscadoreventos/ BoletinEpidemiologico/2022_Boletin_ epidemiologico_semana_2.pdfLee YH, Choe YJ, Cho SI, Kang CR, Bang JH, Oh MD, et al. Effectiveness of Varicella Vaccination Program in Preventing Laboratory-Confirmed Cases in Children in Seoul, Korea. J Korean Med Sci [Internet]. 2016;31(12):1897-1901. doi: https://doi.org/10.3346/ jkms.2016.31.12.1897Siedler A, Rieck T, Tolksdorf K. Strong Additional Effect of a Second Varicella Vaccine Dose in Children in Germany, 2009-2014. J Pediatr [Internet]. 2016;173:202-206.e2. doi: https://doi.org/10.1016/j. jpeds.2016.02.040Leung J, Harpaz R. Impact of the Maturing Varicella Vaccination Program on Varicella and Related Outcomes in the United States: 1994–2012. J Pediat Infect Dis Soc [Internet]. 2016;5(4):395-402. doi: https://doi. org/10.1093/jpids/piv044Hobbelen PHF, Stowe J, Amirthalingam G, Miller L, van Hoek AJ, The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. J Infect [Internet]. 2016;73(3):241-253. doi: https://doi. org/10.1016/j.jinf.2016.05.008Wormsbecker AE, Wang J, Rosella LC, Kwong JC, Seo CY, Crowcroft NS, et al. Twenty Years of Medically- Attended Pediatric Varicella and Herpes Zoster in Ontario, Canada: A Population-Based Study. PLoS ONE [Internet]. 2015;10(7):1-13. doi: https://doi. org/10.1371/journal.pone.0129483Xu Y, Liu Y, Zhang X, Zhang X, Du J, Cai Y, et al. Epidemiology of varicella and effectiveness of varicella vaccine in Hangzhou, China, 2019. Hum Vaccin Immunother [Internet]. 2021;17(1):211-216. doi: https://doi.org/10.1080/21645515.2020.1769395Abdullat M, Hayajneh W, Banni-Issa A, Alshurman A, Marar B, Al-Hajajrah A, et al. Use of health care resources for varicella in the paediatric population, Jordan. East Mediterr Health J [Internet]. 2021;27(2):159-166. doi: https://doi.org/10.26719/2021.27.2.159Chacon-Cruz E, Meroc E, Costa-Clemens SA, Clemens R, Verstraeten T. Economic Evaluation of Universal Varicella Vaccination in Mexico. Pediatr Infect Dis J [Internet]. 2022;41(5):439-444. doi: https://doi. org/10.1097/inf.0000000000003448Akpo EIH, Cristeau O, Hunjan M, Casabona G. Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom. Clin Infect Dis [Internet]. 2021;73(11):e3617-e3626. doi: https://doi.org/10.1093/cid/ciaa1708Marijam A, Safonova E, Scherbakov M, Shpeer E, Van Oorschot D, Rudakova A, et al. Cost effectiveness and budget impact of universal varicella vaccination in Russia. Hum Vaccin Immunother [Internet]. 2022;18(5):2045152. doi: https://doi.org/10.1080/21645 515.2022.2045152Heininger U, Pillsbury M, Samant S, Lienert F, Guggisberg P, Gani R, et al. Health Impact and Costeffectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland. Pediatr Infect Dis J [Internet]. 2021;40(6):e217-e221. doi: https:// doi.org/10.1097/inf.0000000000003136Ávila-Agüero ML, Beltrán S, Brea-del Castillo J, Castillo-Díaz ME, Chaparro LE, Deseda C, et al. Varicella epidemiology in Latin America and the Caribbean. Expert Rev Vaccines [Internet]. 2018;17(2):175-183. doi: https://doi.org/10.1080/14760584.2018.1418327Alvis-Guzmán N, Paternina-Caicedo A, Alvis-Estrada L, De la Hoz-Restrepo F. Costos directos de varicela complicada en una población pediátrica de Colombia. Rev Salud Pública [Internet]. 2011;13(6):921-929. doi: https://doi.org/10.1590/s0124-00642011000600005Torres JP, Maza V, Izquierdo G, Contardo V, Conca N, Ducasse K, et al. Caracterización clínica y de costos de la hospitalización asociada a varicela en niños de la Región Metropolitana y de Valparaíso, Chile. Rev Chilena Infectol [Internet]. 2021;38(5):647-654. doi: https://doi. org/10.4067/s0716-10182021000500647Maglione MA, Das L, Raaen L, Smith A, Chari R, Newberry S, et al. Safety of Vaccines Used for Routine Immunization of U.S. Children: A Systematic Review. Pediatrics [Internet]. 2014;134(2):325–337. doi: https:// doi.org/10.1542/peds.2014-1079Meyer C, Reiter S. Impfgegner und Impfskeptiker Geschichte, Hintergründe, Thesen, Umgang. Bundesgesundheitsbl-Gesundheitsforsch- Gesundheitsschutz [Internet]. 2004;47(12):1182–1188. doi: https://doi.org/10.1007/s00103-004-0953-xhttp://creativecommons.org/licenses/by-nc-nd/2.5/co/Abierto (Texto Completo)Atribución-NoComercial-SinDerivadas 2.5 Colombiahttp://purl.org/coar/access_right/c_abf2Vol. 26 Núm. 1 (2023): abril - julio 2023: Niño, Adolescente, Varicela; 12-20Cobertura de VacunaciónIncidenciaNiñoVacuna contra la VaricelaVaricelaMedical sciencesLife sciencesVaccination CoverageIncidenceChildChickenpox VaccineChikenpoxHealth sciencesCiências médicasCiências da vidaCiências da saúdeCobertura VacinalIncidênciaCriançaVacina contra VaricelaVaricelaCiencias médicasCiencias de la vidaCiencias de la saludCobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud BosqueCoverage of and Barriers to Varicella Vaccination in Children at Fundación Salud BosqueCobertura e barreiras à vacinação contra varicela em crianças que consultaram a Fundação Salud BosqueArticleinfo:eu-repo/semantics/articleArtículohttp://purl.org/coar/resource_type/c_2df8fbb1http://purl.org/coar/resource_type/c_6501http://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85Universidad Autónoma de Bucaramanga UNABFacultad Ciencias de la SaludORIGINALArtículo.pdfArtículo.pdfArtículoapplication/pdf847515https://repository.unab.edu.co/bitstream/20.500.12749/26187/1/Art%c3%adculo.pdf15483658392edbcc1efe68f6fd024617MD51open accessLICENSElicense.txtlicense.txttext/plain; charset=utf-8183https://repository.unab.edu.co/bitstream/20.500.12749/26187/2/license.txt737346e09d47a3db691f1370de49426aMD52open accessTHUMBNAILArtículo.pdf.jpgArtículo.pdf.jpgIM Thumbnailimage/jpeg13495https://repository.unab.edu.co/bitstream/20.500.12749/26187/3/Art%c3%adculo.pdf.jpg8f6fb43ff5841648fc6f3d88bc2d2cf9MD53open access20.500.12749/26187oai:repository.unab.edu.co:20.500.12749/261872024-08-23 22:02:24.852open accessRepositorio Institucional | Universidad Autónoma de Bucaramanga - UNABrepositorio@unab.edu.coTGFzIHB1YmxpY2FjaW9uZXMgZGUgbGEgcmV2aXN0YSBNZWRVTkFCIGVzdMOhbiBiYWpvIHVuYSBMaWNlbmNpYSBkZSBBdHJpYnVjacOzbiBkZSBCaWVuZXMgQ29tdW5lcyBDcmVhdGl2b3MgKENyZWF0aXZlIENvbW1vbnMsIENDKSB0aXBvIDQuMCwgY29uIGRlcmVjaG9zIGRlIGF0cmlidWNpw7NuIHkgbm8gY29tZXJjaWFs |